Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.82 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | PRKCG | P05129 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752565 | 1.00 | ESR1 (0.82) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL6227056 | 0.95 | ESR1 (0.74) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL6225728 | 0.95 | ESR1 (0.74) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL23671979 | 0.90 | ESR1 (1.00) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL21496962 | 0.90 | ESR1 (1.00) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| Iodide SCHEMBL30559876 | 0.89 | ESR1 (1.00) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL6227843 | 0.89 | ESR1 (0.65) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL9452012 | 0.88 | ESR1 (0.84) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL6948715 | 0.84 | ESR1 (0.79) | ESR1CYP19A1CYP3A4ESR2MAPT | |
| SCHEMBL6947496 | 0.84 | ESR1 (0.79) | ESR1CYP19A1CYP3A4ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023012353-A1 | COMPOUNDS FOR USE IN THE THERAPEUTIC TREATMENT OF BATTEN DISEASE | FONDAZIONE TELETHON (IT) | 2023-02-09 | — | — | WO | claimed |
| WO-2008139152-A1 | N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-11-20 | — | — | WO | claimed |
| EP-4551251-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790075-A | CNS targeting complexes and uses thereof | 达因疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240366562-A1 | GYNECOMASTIA AND/OR MASTALGIA TREATMENT | BIOZEN LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| CN-117956986-A | Gynecomastia and/or mastodynia treatment | I·查托维茨 | 2024-04-30 | — | — | CN | disclosed |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024011150-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023012353-A1 | COMPOUNDS FOR USE IN THE THERAPEUTIC TREATMENT OF BATTEN DISEASE | FONDAZIONE TELETHON (IT) | 2023-02-09 | — | — | WO | disclosed |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| WO-2019204764-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2008139152-A1 | N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139152-A1 | N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2007098090-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH N-OXIDES OF ESTROGEN RECEPTOR MODULATORS | NOVACEA, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2005015243-A1 | METHOD FOR IDENTIFYING ACTIVE AND/OR INACTIVE METABOLITES; AND NOVEL ACTIVE METABOLITES | KIADIS B.V. (NL) | 2005-02-17 | — | — | WO | disclosed |
| EP-1505395-A1 | Method for identifying active and/or inactive metobolites; and novel active metabolites | Kiadis B.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | SERPINA2, FABP1, TTR | ESR1 4834/4885CYP19A1 3711/4885CYP3A4 4382/4885 |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | SERPINA2, FABP1, TTR | ESR1 4834/4885CYP19A1 3711/4885CYP3A4 4382/4885 |
| US-20240366562-A1 | GYNECOMASTIA AND/OR MASTALGIA TREATMENT | CYP19A1, GPER1, SHBG | ESR1 7/4885CYP19A1 1/4885CYP3A4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.